Huntington's disease (HD) belongs to a family of eight inherited, unbeatable neurodegenerative diseases caused by the abnormal expansion of a polyglutamine (polyQ) stretch. Many of these diseases are characterized by protein deposits called inclusion bodies (IBs), there pathogenic roles are controversial. We made a model of Huntington's disease with neurons that recapitulates polyQ-dependent neuron-specific death and IB formation. In the previous funding period, we built a robotic microscope to monitor pathological changes in single neurons over time and to quantitate the extent to which a specific early change predicts whether a neuron lives or dies. We found that the risk of death in neurons with polyQ-expanded huntingtin (htt) decreases, at least temporarily, upon IB formation but it increases with polyQ length in neurons without IBs. We developed an antibody (mAb) 3B5H10 that selectively binds a disease-associated conformation of polyQ in htt, which is reduced upon incorporation of htt into an IB. We hypothesize that IB formation is a beneficial coping response by neurons to sequester more toxic, soluble forms of polyQ-expanded htt. Recognition of htt by mAb 3B5H10 predicts neuronal death, suggesting that this polyQ conformation might be pathogenic. Levels of polyQ-expanded htt increase before IB formation, possibly indicating a defect in htt degradation. However, it is not known whether impaired proteasome degradation of htt causes IB formation or leads to polyQ-dependent death. Whether IB formation is protective per se or simply a marker of longevity is also unclear. The structure of a disease-associated polyQ stretch is not known, nor is it clear whether aggregation intermediates of polyQ-expanded htt predict death better than the conformation bound by mAb 3B5H10. We will use the tools developed during the previous period to accomplish the following Specific Aims:
Specific Aim 1. To assess the relationship between proteasome function and IB formation and determine if proteasome dysfunction is a major predictor of polyQ-dependent death.
Specific Aim 2. To determine if IB formation provides a measure of protection against the deleterious effects of polyQ-expanded htt on neuronal function and survival.
Specific Aim 3. To elucidate neurotoxic species of polyQ-expanded htt.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
2R01NS039074-05A1
Application #
6932629
Study Section
Special Emphasis Panel (ZRG1-CDIN (01))
Program Officer
Oliver, Eugene J
Project Start
2000-07-01
Project End
2010-01-31
Budget Start
2005-02-15
Budget End
2006-01-31
Support Year
5
Fiscal Year
2005
Total Cost
$481,065
Indirect Cost
Name
J. David Gladstone Institutes
Department
Type
DUNS #
099992430
City
San Francisco
State
CA
Country
United States
Zip Code
94158
Cobb, Melanie M; Ravisankar, Abinaya; Skibinski, Gaia et al. (2018) iPS cells in the study of PD molecular pathogenesis. Cell Tissue Res 373:61-77
Aron, Rebecca; Pellegrini, Pasquale; Green, Edward W et al. (2018) Deubiquitinase Usp12 functions noncatalytically to induce autophagy and confer neuroprotection in models of Huntington's disease. Nat Commun 9:3191
Mason, Amanda R; Elia, Lisa P; Finkbeiner, Steven (2017) The Receptor-interacting Serine/Threonine Protein Kinase 1 (RIPK1) Regulates Progranulin Levels. J Biol Chem 292:3262-3272
Skibinski, Gaia; Hwang, Vicky; Ando, Dale Michael et al. (2017) Nrf2 mitigates LRRK2- and ?-synuclein-induced neurodegeneration by modulating proteostasis. Proc Natl Acad Sci U S A 114:1165-1170
Oliveira, Ana Osório; Osmand, Alexander; Outeiro, Tiago Fleming et al. (2016) ?B-Crystallin overexpression in astrocytes modulates the phenotype of the BACHD mouse model of Huntington's disease. Hum Mol Genet 25:1677-89
Moruno Manchon, Jose Felix; Uzor, Ndidi-Ese; Finkbeiner, Steven et al. (2016) SPHK1/sphingosine kinase 1-mediated autophagy differs between neurons and SH-SY5Y neuroblastoma cells. Autophagy 12:1418-24
Kratter, Ian H; Zahed, Hengameh; Lau, Alice et al. (2016) Serine 421 regulates mutant huntingtin toxicity and clearance in mice. J Clin Invest 126:3585-97
Haston, Kelly M; Finkbeiner, Steven (2016) Clinical Trials in a Dish: The Potential of Pluripotent Stem Cells to Develop Therapies for Neurodegenerative Diseases. Annu Rev Pharmacol Toxicol 56:489-510
Shaby, Benjamin A; Skibinski, Gaia; Ando, Michael et al. (2016) A three-groups model for high-throughput survival screens. Biometrics 72:936-44
Lee, Jong-Min; Kim, Kyung-Hee; Shin, Aram et al. (2015) Sequence-Level Analysis of the Major European Huntington Disease Haplotype. Am J Hum Genet 97:435-44

Showing the most recent 10 out of 63 publications